CytomX Therapeutics, Inc. Goodwill & Intangibles Disclosure
6. Intangible Asset
The intangible asset is being amortized over the estimated lives of the patents which average 12 years. The amortization expense for each of the years ended December 31, 2024 and 2023 was $0.1 million.
|
|
December 31, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
|
|
(in thousands) |
|
|||||
PROBODY platform intangible asset |
|
$ |
1,750 |
|
|
$ |
1,750 |
|
Less accumulated amortization |
|
|
(1,167 |
) |
|
|
(1,021 |
) |
|
|
$ |
583 |
|
|
$ |
729 |
|
Want the next CytomX Therapeutics, Inc. goodwill & intangibles disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment CytomX Therapeutics, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Goodwill & Intangibles Disclosures
Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.
Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.